Product Description
Overall, the global local antimicrobial periodontal treatment market was valued at over $240 million in 2025. This is expected to decrease over the forecast period at a CAGR of -0.7% to just over $230 million.
The full report suite includes local antimicrobial periodontal treatment only. The market is analyzed as a whole and not further segmented.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Global Local Antimicrobial Periodontal Treatment Market Trends
Reimbursement limitations continue to influence treatment decisions in periodontal care, as dental insurance coverage for advanced procedures remains limited in many markets. This can discourage patients from pursuing higher-cost surgical interventions, supporting the continued use of lower-cost periodontal therapies, including local antimicrobial treatments administered alongside scaling and root planing. These therapies provide a cost-conscious option for managing periodontal disease, particularly in patients with mild to moderate conditions.
Global Local Antimicrobial Periodontal Treatment Market Share Insights
- OraPharma’s flagship product, ARESTIN®, currently controls the majority share of the local antimicrobial market for periodontal therapy. ARESTIN® is a local antimicrobial adjunct to scaling and root planing that utilizes 1 mg of minocycline hydrochloride microspheres to reach deep periodontal pockets. The product was originally launched in 1996 and received Food and Drug Administration (FDA) approval in 2001. In 2018, Valeant Pharmaceuticals permanently changed its name to Bausch Health Companies in order to distance itself from the negative press that Valeant Pharmaceuticals was receiving in response to significant price increases. While the product continues to maintain a dominant market share, ARESTIN® is seeing year-over-year revenue decreases and is consistently falling short of its annual revenue forecasts. The product is not losing market share to other local antimicrobials but rather is being harmed by the overall saturation of the market and the rapidly increasing popularity of periodontal laser therapy. The decline of the North American local antimicrobial market will slowly erode the global market share of ARESTIN® unless a significant change in market dynamics occurs.
- PerioChip® emerged as the second top competitor in the global antimicrobial periodontal treatment market, securing the leading position in Europe. The product is sold worldwide through a broad network of distributors. It is sold by Dexcel Pharma via its subsidiaries and partners in Germany, the U.K., Benelux, Austria and other countries. PerioChip® is sold by Curaden Healthcare in Italy and by Karr Denta in Switzerland. Founded in 1968, Dexcel Pharma is Israel’s largest private pharmaceutical company. In addition to its PerioChip®, the company’s portfolio includes over 85 brands and generic products, as well as drug delivery technologies. PerioChip® comes in the form of a small biodegradable gelatin matrix that can be placed manually into a periodontal pocket. Each chip contains 2.5 mg of chlorohexidine digluconate, an antiseptic agent. PerioChip® is widely regarded as an exceptional treatment option for periodontal pockets, which is why it has seen international success for over two decades.
- Ligosan achieved the second-largest share in the European market for local antimicrobial periodontal treatment and ranked third globally in 2025. The treatment has been authorized in Europe since 2013 under the names Ligosan®, Adjusan® and Ligoslo®. Ligosan® Slow Release was launched in Germany in 2010. It is primarily distributed by Kulzer. In contrast to PerioChip®, Ligosan® comes in a form of gel with an active ingredient doxycycline, which is released into the periodontal pockets. Kulzer is a part of the Mitsui Chemicals Group and one of the leading global dental companies. The company’s portfolio spans over digital dentistry, tooth preservation, prosthetics and periodontal treatment.
Global Local Antimicrobial Periodontal Treatment Market Segmentation Summary
- Local Antimicrobial Periodontal Treatment Market
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Region | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
